Full-Time

Category Manager

Posted on 1/24/2026

Agilent Technologies

Agilent Technologies

10,001+ employees

Provides eProcurement automation and hosted catalogs

Compensation Overview

$105.3k - $164.5k/yr

+ Bonus + Stock

Company Does Not Provide H1B Sponsorship

Wilmington, DE, USA

In Person

Category
Operations & Logistics (1)
Requirements
  • Bachelor’s degree in Supply Chain Management, Engineering, Business, or a related field.
  • 8+ years of relevant experience in strategic sourcing, category management, or supply chain management.
  • Experience in specialty materials and/or specialty process would be advantageous.
  • Global sourcing experience and working with international suppliers.
  • Proficiency in strategic sourcing methodologies, supplier evaluation, and contract negotiation.
  • Experience with Total Cost of Ownership and Technology, Quality, Responsiveness, Delivery, Cost frameworks.
  • Ability to conduct risk analysis and develop mitigation strategies.
  • Proven ability to lead cross-functional teams and influence stakeholders at all levels.
  • Strong project management and change management skills.
  • Excellent negotiation, presentation, and communication skills.
  • Ability to work in a fast-paced, matrixed, and global environment.
  • Proficiency in ERP systems (e.g., SAP, Oracle).
  • Experience with e-sourcing tools, supplier management platforms, and data analytics tools (e.g., Power BI, Excel).
  • Familiarity with contract management systems and procurement platforms.
Responsibilities
  • Strategic Category Analysis & Direction Setting
  • Partner and Stakeholder Alignment
  • Develop a strong understanding of business requirements. Work with partners to clearly understand their direction and needs
  • Internalize the requirements and define what needs to be delivered to meet their needs, also identify additional opportunities to deliver new value-add
  • Develop a strong understanding of the supply market, its capability, direction, trends, etc. Understand who the best suppliers are; the niches they serve, their capability, etc.
  • Align sourcing strategy to support key stakeholder's short and long-term requirements
  • Provide partners with the highest quality products and services
  • Periodically survey partners to assess changing business or technology needs
  • Work with management to translate the business requirements into objectives and goals for the Category
  • Lead the development of the Category strategy. Develop the appropriate initiatives to achieve the strategy and meet business requirements
  • Establish sourcing targets based on the business needs and requirements. Develop the appropriate sourcing strategy and initiatives and plans to meet and / or exceed the targets. Also, develop the appropriate supplier performance expectations utilizing the TQRDC categories. Ensure expectations are tied to business needs. Communicate any changes in expectations in a timely manner
  • Establish the total cost of ownership targets based on business requirements. Implement the appropriate initiatives to meet and/or exceed targets
  • Execute and maintain the Category strategy. Report progress and results to management and business partners regularly
  • Manage the worldwide supply base in accordance with the category strategy
  • Evaluate changes in business requirements and conditions; update strategy accordingly
  • Stay current with industry developments for the Category. Conduct research using various sources such as trade journals, internet, ISM, business news and internal and external networking
  • Maintain a basic technical knowledge
  • Keep supply market data up to date. Maintain an in-depth understanding of the supply market, understand suppliers' positions within the market, the niches they serve; competition, new market entrants; etc.
  • Maintain continuous assurance of supply - serve as an escalation point for AOS issues
  • Evaluates production and R&D requirements. Determines if a current supplier can meet the needs
  • Identifies, evaluates, and selects new suppliers that meet Agilent's business requirements. Conducts supplier audits for the engineers to properly evaluate potential suppliers
  • Prepares and evaluates quotation packages. Establish cost standards and analyze variances for new parts/products. Drive cost optimization throughout the supply chain and provide reporting.
  • Ensure supply base is able to meet current and future business requirements
  • Prior to selecting a new supplier, assesses the need for a contract, establishes performance expectations, and reviews financial stability
  • Upon supplier selection, develops and negotiates the appropriate contracts that protect Agilent's interests; gets the best total cost, and minimizes business risk. Review and discuss their business recovery plan and succession plan if this is a critical part or supplier
  • Develops and negotiates the appropriate contracts that protect Agilent's interests; gets the best total cost, and minimizes business risk. Review and discuss their business recovery plan and succession plan if this is a critical part or supplier
  • Conduct the appropriate analysis for the Category to analyze 'total cost' and set the appropriate targets. Utilize the appropriate tools ('should cost models' or other forms of analysis) to ensure cost structure is optimized relative to external benchmarks
  • Execute TQRDC surveys, analyzes data, and prepare supplier feedback. Meet with management to share supplier results, plans and gain their support. Meets with top suppliers at least annually to review direction, assure alignment, and review performance results. Hold suppliers accountable for meeting commitments and performance expectations. Work with suppliers to develop performance improvement plans (as needed) and monitor progress
  • Ensure quality management expectations are set. Hold suppliers accountable for meeting quality requirements (quality, on-time delivery etc.) Ensure Agilent's SQSR's are met based on corporate guidelines. Monitors environmental requirements and ensures compliance
  • Conduct appropriate risk analysis; identify options and work to minimize risk from impacting business
  • Supplier Liability Reporting: accountable for reporting and representing inventory liability data per contractual purchase agreements
Desired Qualifications
  • Experience in a fast-paced, matrixed, and global environment is listed as a requirement but is also desirable
  • None, since the job posting does not explicitly separate Desirable items beyond what is in Qualifications.

Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Eight FDA-approved PD-L1 IHC 22C3 pharmDx indications drive companion diagnostics revenue.
  • AI-enabled imaging software differentiates Agilent amid sector vulnerability to funding fluctuations.
  • Analysts project $8.6 billion revenue and $2 billion earnings by 2029.

What critics are saying

  • Biocare integration failure destroys $200–300M expected value within 12–24 months.
  • Supreme Court CRISPR patent denial enables competitors to develop rival enrichment workflows.
  • Research funding contraction cuts recurring consumables revenue $200–600M annually within 12–18 months.

What makes Agilent Technologies unique

  • Biocare Medical acquisition adds 300+ specialized antibodies with double-digit growth since 2021.
  • BioTek Cytation 9 combines high-content imaging with automation for research labs.
  • Oxford Nanopore partnership enables structural variant analysis and methylation profiling applications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Company News

Yahoo Finance
Apr 3rd, 2026
Agilent loses CRISPR patent case but launches BioTek Cytation 9 imaging platform

Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.

Business Wire
Mar 26th, 2026
Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal or GEJ carcinoma

Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.

Yahoo Finance
Mar 23rd, 2026
Agilent leads research tools stocks with $1.8B Q4 revenue, up 7% amid sector decline

Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.

GS MedTech
Mar 9th, 2026
Agilent Technologies acquires US firm BioTek Instruments

Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t

Agilent Technologies
Mar 9th, 2026
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.  Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction

INACTIVE